Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer von RUDIN, Charles M, HANN, Christine L, RANSON, Malcolm R, DIVE, Caroline, MCKEEGAN, Evelyn M, CHYLA, Brenda J, DOWELL, Barry L, CHAKRAVARTTY, Arunava, NOLAN, Cathy E, RUDERSDORF, Niki, BUSMAN, Todd A, MABRY, Mack H, GARON, Edward B, KRIVOSHIK, Andrew P, HUMERICKHOUSE, Rod A, SHAPIRO, Geoffrey I, GANDHI, Leena, DE OLIVEIRA, Moacyr Ribeiro, BONOMI, Philip D, ROSS CAMIDGE, D, CHU, Quincy, GIACCONE, Giuseppe, KHAIRA, Divis, RAMALINGAM, Suresh S

Volltext

Phase 3, randomized, double-blind, placebo-controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naïve patients with acute myeloid leukemia von Potluri, Jalaja, Xu, Tu, Hong, Wan-Jen, Mabry, Mack H.

Volltext

Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes von Fong, Chun Yew, Wei, Andrew H., Frattini, Mark G., Jacoby, Meagan, Borate, Uma, Gotze, Katharina S., Garcia, Jacqueline Suen, Pollyea, Daniel Aaron, Holes, Leanne, Zhou, Ying, Fakouhi, Kaffa Mussumeh, Leverson, Joel, Harb, Jason G, Agarwal, Suresh K., Attarchi, Faraneh, Mabry, Mack H., Hong, Wan-Jen, Jahn, Thomas Michael, Fenaux, Pierre, Garcia-Manero, Guillermo

Volltext

Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy von Pollyea, Daniel Aaron, Dinardo, Courtney Denton, Thirman, Michael J., Letai, Anthony, Wei, Andrew H., Jonas, Brian Andrew, Arellano, Martha Lucia, Frattini, Mark G, Kantarjian, Hagop M, Chyla, Brenda, Zhu, Ming, Potluri, Jalaja, Humerickhouse, Rod, Mabry, Mack H., Konopleva, Marina, Pratz, Keith William

Volltext

Abstract A92: A phase 1 safety and pharmacokinetic study of navitoclax in combination with docetaxel in patients with solid tumors von Eskens, Ferry ALM, Gutierrez, Martin, Cosgrove, David, Puglisi, Martina, van Doorn, Leni, Blanco, Montserrat, de Jonge, Maja JA, Moran, Kirsty, Walther, Axel, Yang, Jianning, Busman, Todd A., Franklin, Catherine A., Mabry, Mack H., Humerickhouse, Rod A., Molife, Lulama Rhoda

Volltext

The genotype of the human cancer cell: Implications for risk analysis von Williams, Jerry R., Russell, James, Dicello, John F., Mabry, Mack H.

Volltext

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, ph... von DiNardo, Courtney D, Pratz, Keith W, Letai, Anthony, Jonas, Brian A, Wei, Andrew H, Thirman, Michael, Arellano, Martha, Frattini, Mark G, Kantarjian, Hagop, Popovic, Relja, Chyla, Brenda, Xu, Tu, Dunbar, Martin, Agarwal, Suresh K, Humerickhouse, Rod, Mabry, Mack, Potluri, Jalaja, Konopleva, Marina, Pollyea, Daniel A

Volltext

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia von Wei, Andrew, Strickland, Stephen A., Roboz, Gail J., Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L., Martinelli, Giovanni, Walter, Roland B., Enjeti, Anoop, Fakouhi, Kaffa, Darden, David E., Dunbar, Martin, Zhu, Ming, Agarwal, Suresh, Salem, Ahmed H., Mabry, Mack, Hayslip, John

Volltext

Second Primary Cancers Related to Smoking and Treatment of Small-Cell Lung Cancer von Tucker, Margaret A., Murray, Nevin, Shaw, Edward G., Ettinger, David S., Mabry, Mack, Huber, Martin H., Feld, Ronald, Shepherd, Frances A., Johnson, David H., Grant, Stefan C., Aisner, Joseph, Johnson, Bruce E.

Volltext

An achaete-scute homologue essential for neuroendocrine differentiation in the lung von Borges, M, Linnoila, R I, van de Velde, H J, Chen, H, Nelkin, B D, Mabry, M, Baylin, S B, Ball, D W

Volltext

An achaete-scute homologue essential for neuroendocrine differentiation in the lung von Borges, Michael, Linnoila, R. Ilona, van de Velde, Helgi J. K, Chen, Herbert, Nelkin, Barry D, Mabry, Mack, Baylin, Stephen B, Ball, Douglas W

Volltext

ELEVATED DT-DIAPHORASE ACTIVITY AND MESSENGER-RNA CONTENT IN HUMAN NON-SMALL-CELL LUNG-CARCINOMA - RELATIONSHIP TO THE RESPONSE OF LUNG-TUMOR XENOGRAFTS TO MITOMYCIN-C von MALKINSON, AM, SIEGEL, D, FORREST, GL, GAZDAR, AF, OIE, HK, CHAN, DC, BUNN, PA, MABRY, M, DYKES, DJ, HARRISON, SD, ROSS, D

Volltext

A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma an eastern cooperative oncology group study von KALEMKERIAN, G. P, JIROUTEK, M, ETTINGER, D. S, DORIGHI, J. A, JOHNSON, D. H, MABRY, M

Volltext

Differential expression of nuclear envelope lamins A and C in human lung cancer cell lines von KAUFMANN, S. H, MABRY, M, JASTI, R, SHAPER, J. H

Volltext

A Phase II study of all‐trans‐retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma von Kalemkerian, Gregory P., Jiroutek, Michael, Ettinger, David S., Dorighi, John A., Johnson, David H., Mabry, Mack

Volltext

Effect of v- rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin von Kaufmann, Scott H., Kalemkerian, Gregory P., Jasti, Rajani, Mabry, Mack

Volltext